Active Biotech Ab · OMXSTO:ACTI

Active Biotech Ab — Investor Presentation (March 2024)

29 slides from Active Biotech Ab's investor presentation, March 2024

  1. Slide 1: Active Biotech

  2. Slide 2: Disclaimer

    Disclaimer • Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or i

  3. Slide 3: Active Biotech in Brief

    Active Biotech in Brief Clear focus on specialist disease areas Finance & Corporate • Large unmet medical need and value potential • Listed on Nasdaq Stockholm (ticker: ACTI) • Hematological cancers (clinical Ph I/IIa study ongoing) • Market cap SEK 240 M, USD 22,6 M* • Inflammatory eye disorders (c

  4. Slide 4: Immunomodulation to Treat Cancer and Inflammation

    Immunomodulation to Treat Cancer and Inflammation Small molecules Antibody based immunotherapy - myeloid cell modulation - tumor targeting superantigen Tasquinimod Naptumomab Superantigen-dependent cellular cytotoxicity Laquinimod Abbrev:, MDSC – Myeloid derived suppressor cell; HDAC4 – Histone deac

  5. Slide 5: Valuable Clinical Pipeline in Specialist Indications

    Valuable Clinical Pipeline in Specialist Indications LAQUINIMOD 5

  6. Slide 6: Key Collaborations with Academic Partners

    Key Collaborations with Academic Partners Tasquinimod Multiple myeloma • Yulia Nefedova, M.D., Ph.D. Associate Professor, Immunology, Microenvironment & Metastasis Program, The Wistar Institute Cancer Center, Philadelphia, US • Kim De Veirman, PhD, Brussels Health Campus VUB, Brussels Myelofibrosis

  7. Slide 7: Tasquinimod: New Type of Treatment for Hematological Malignances with Unmet Medical Need

    Tasquinimod: New Type of Treatment for Hematological Malignances with Unmet Medical Need Ongoing study Core focus High value opportunity Multiple myeloma (MM) Myelofibrosis (MF) Myelodysplastic syndrome (MDS) Blocking of the tumor-supportive bone Disease modifying by targeting the Restoration of hem

  8. Slide 8: Multiple Myeloma: An Incurable Blood Cancer

    Multiple Myeloma: An Incurable Blood Cancer • Multiple myeloma develops in the bone marrow • Uncontrollable growth of plasma cells • Formation of new blood cells prevented • Leads to bone pain, fractures, anemia and other severe complications, e g renal failure and infections • Survival has increase

  9. Slide 9: Tasquinimod: Synergy in Combination with Anti-Myeloma Treatments

    Tasquinimod: Synergy in Combination with Anti- Myeloma Treatments Tasquinimod in combination with Tasquinimod in combination with proteasome inhibitors (PIs) an immunomodulatory drug (IMiD) Vehicle Vehicle Vehicle tasq 400 400 Tumor Area (mm2) tasq 300 ixa len Tumor Area (mm2) tasq tasq + len Tumor

  10. Slide 10: Ongoing Ph Ib/IIa Study in Multiple Myeloma

    Ongoing Ph Ib/IIa Study in Multiple Myeloma Patients Patients Primary endpoint MM relapsed or refractory after ≥1 line of anti-MM therapy and refractory or MM relapsed or refractory after Safety & tolerability, intolerant to lenalidomide, pomalidomide, bortezomib, carfilzomib, and an anti- ≥1 line o

  11. Slide 11: Multiple Myeloma: Market Driven by Novel Treatments

    Multiple Myeloma: Market Driven by Novel Treatments ~880,000 people Total patients treated → Duplet → Triplet → Quadruplet → Quintuplet multiple myeloma drug combination regimens ~215,000 people Treated in 2 line ~295,000 Treated in 3+ lines Eight major markets: $22bn in sales in people 2027 Commerc

  12. Slide 12: Myelofibrosis: Rare Blood Cancer

    Myelofibrosis: Rare Blood Cancer Myelofibrosis (MF) – In brief Tasquinimod Ameliorates Hallmarks of MF in a Mouse model • A rare blood cancer with an annual incidence of 0.4 - 1.3 cases per 100 000 people in Europe • Market estimated to above USD 2.9 billion* • Abnormal production of blood-forming c

  13. Slide 13: Combination with Tasquinimod and a BET inhibitor or a JAK inhibitor is Effective in a Mouse Model of MF

    Combination with Tasquinimod and a BET inhibitor or a JAK inhibitor is Effective in a Mouse Model of MF* Reduced spleen length Reduced spleen size Increased survival ✱✱ 40 Vehicle ✱✱✱ 10 weeks of treatment Spleen length (in mm) ✱ ✱ 100 30 mg/kg Tasquinimod 30 ✱✱✱✱ 30 mg/kg ruxolitinib ✱✱✱✱ ✱ ✱ 75 %

  14. Slide 14: Tasquinimod: Development in Myelofibrosis

    Tasquinimod: Development in Myelofibrosis • Global patent license agreement between Active Biotech and Oncode Institute/Erasmus MC since Feb 2022 • Clinical PoC with tasquinimod alone in Europe, to start in 2024 • Study funded by Oncode Institute • To be conducted by HOVON in the Netherlands and Ger

  15. Slide 15: Myelofibrosis: Need for Disease Modifying Treatment

    Myelofibrosis: Need for Disease Modyfing Treatment 85,000 people Total prevalent cases for myelofibrosis (primary and secondary MF) • Major unmet medical need • Only one drug class approved 67,200 people Total treated patients Commercial potential: USD 750 million /year Eight major markets: USD 2.9

  16. Slide 16: Laquinimod: Novel Treatment for Eye Disorders

    Laquinimod: Novel Treatment for Eye Disorders Core focus High value indications Non-infectious uveitis Eye disorders with excessive neovascularization Laquinimod induces immune tolerance by Laquinimod reduces the pro-inflammatory targeting antigen presenting cells and angiogenic response by targetin

  17. Slide 17: Non-Infectious Uveitis: High Medical Need

    Non-Infectious Uveitis: High Medical Need • Standard treatments Laquinimod • Corticosteroids: local and systemic • Immunosuppressants • Monoclonal antibodies • High medical need for new therapy to improve efficacy and limit side effects • As a steroid-sparing regimen Current treatment of non-infecti

  18. Slide 18: Laquinimod Works Both Topically and Orally

    Laquinimod Works Both Topically and Orally Topical laquinimod Oral laquinimod Inhibition of Histological ocular evaluation Topical endoscopic fundus imaging (TEFI) experimental uveitis by ✱✱✱ laquinimod is associated ✱✱✱ Posterior histological scores 30 with: Posterior clinical scores 6 Vehicle (ora

  19. Slide 19: Laquinimod Development Program in Eye Disorders

    Laquinimod Development Program in Eye Disorders • Innovative gel like eye drop formulation*, developed, optimized and manufactured • Available IND regulatory package complemented with required pre-clinical eye toxicity & tolerance studies • Safety and tolerability confirmed in clinical Phase I study

  20. Slide 20: Safety and Tolerability Profile of Laquinimod Eye Drops Confirmed in Healthy Subjects

    Safety and Tolerability Profile of Laquinimod Eye Drops Confirmed in Healthy Subjects Single-Ascending Dose Multiple Dose • Laquinimod or placebo • Laquinimod or placebo Subjects Dose-escalation based on Dose/Duration: (N=54) • Adverse events • Once daily for up to 21 days • Eye examinations Assessm

  21. Slide 21: Laquinimod: Clinical Development in Uveitis

    Laquinimod: Clinical Development in Uveitis ✓Generate data on safety and tolerability of laquinimod eye drops in healthy subjects • Safety and tolerability confirmed in completed phase I study • Confirm biodistribution in the eye after ocular administration to patients • Study to start in Q1 2024 at

  22. Slide 22: Uveitis: Significant Opportunity

    Uveitis: Significant Opportunity Significant opportunity in segment of non-infectious non-anterior uveitis in 9MM, forecasts for 2029 ~258,000 • Corticosteroids only effective in 60% people Total diagnosed • Clinical consequences serious prevalent cases ~205,000 people Total treated cases (1LoT: cor

  23. Slide 23: Naptumomab: Tumor Directed Immunotherapy

    Naptumomab: Tumor Directed Immunotherapy Combination with Combination with Combination with checkpoint inhibition chemo chemotherapy CART Cell Treatment Preclinical data suggest synergy Preclinical data suggest synergy Preclinical data suggest synergy with checkpoint inhibitors with chemotherapy wit

  24. Slide 24: Naptumomab: Clinical Studies

    Naptumomab: Clinical Studies • Phase IIa study of naptumomab + docetaxel in lung cancer Treatment and Endpoints (NCT04880863) Naptumomab + Docetaxel after Obinutuzumab • Patients (N=35): Progressive NSCLC, no prior docetaxel, prior exposure to pre-treatment checkpoint inhibitor • Status: Second stag

  25. Slide 25: Safety and Preliminary Activity of Naptumomab Estafenatox and Durvalumab Interim Results

    Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors Interim Results from a Phase Ib Trial Poster presentation at AACR 2023 • 59 patients with various advanced/metastatic solid tumors and a median of 3 prior lines • Recom

  26. Slide 26: Projected Clinical Milestones Through 2024

    Projected Clinical Milestones Through 2024 Tasquinimod • Ph Ib/IIa combination with IRd in multiple myeloma: Final results H2 2024 • Ph II Myelofibrosis • Start of study in Europe, Q3 2024 • Start of study in US, H1 2024 Laquinimod • Clinical biodistribution study of eye drop • Start of study, Q1 20

  27. Slide 27: Financials For the Period January – December, 2023

    Financials For the Period January – December, 2023 • Operating expenses January – December, 2023 MSEK 46,5 (57,9) a 24% reduction reflecting reduced clinical and CMC costs. • Rights issue concluded in Q4, 2023 added 41,8 MSEK to liquidity after issue costs • Available cash at Dec. 31, 2023 - MSEK 36

  28. Slide 28: Management

    Management Helén Tuvesson Hans Kolam Erik Vahtola President & CEO CFO CMO Born 1962. CEO since 2017. Born 1951. CFO since 2000. Born 1976. CMO since 2022. Education: MSc, PhD in cell and molecular Education: B.Sc in Business Administration Education: Medical Doctor (MD) and PhD in biology in medical

  29. Slide 29: www.activebiotech.com

    Acti ¢ Biotech /) www.activebiotech.com 29

Active Biotech — Investor Presentation (March 2024) on 6ix